Clinical Impact of Drug-Coated Balloon-Based Percutaneous Coronary Intervention in Coronary Artery Disease Patients With Chronic Heart Failure.

Abstract

Background: Drug-coated balloon (DCB) is a novel treatment option for percutaneous coronary intervention (PCI). The presence of heart failure (HF) in patients with coronary artery disease (CAD) is associated with a poor prognosis. However, the clinical significance of DCB-based PCI in CAD patients with HF is unknown.

Methods and results: This was a retrospective analysis of a cohort study from a prospective, single center registry from 2015 to 2024. We enrolled 258 CAD patients with chronic HF who underwent PCI with DCB or in combination with a drug-eluting stent (DES). Propensity score matching analysis was performed between the DCB-based PCI and DES-only PCI groups. The primary endpoint of this study was all-cause mortality. Baseline clinical characteristics were comparable between the groups. The total DES number and length were significantly reduced in patients with DCB-based PCI than in those with DES-only PCI. Kaplan-Meier analysis revealed that the DCB-based PCI group had a significantly lower rate of all-cause mortality compared with the DES-only group (log-rank test, P=0.04).

Conclusions: In CAD patients with chronic HF, DCB-based PCI was associated with a lower risk of mortality compared with DES-only PCI.